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             Abstract 
 
The in vitro antimicrobial activity of iclaprim, a novel diaminopyrimidine, against common 
respiratory bacteria remained unchanged in the presence of pulmonary surfactant (Survanta®) at 
concentrations that greatly antagonized the antimicrobial activity of daptomycin.  These results 
indicate that iclaprim could be a potential treatment for pneumonia caused by susceptible and 
multidrug resistant bacteria.   
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1. Introduction 
Iclaprim represents a novel diaminopyrimidine, which inhibits bacterial dihydrofolate 
reductase (DHFR) and is active against emerging drug-resistant pathogens (Sader et al., 2009; 
Schneider et al., 2003).  Iclaprim exhibits potent in vitro activity against Staphylococcus aureus, 
Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and atypical bacteria 
(i.e., Legionella pneumophila, Chlamydia pneumoniae, and Mycloplasma pneumoniae) that 
cause pneumonia (Sader et al., 2009; Morrissey et al., 2009).  Iclaprim demonstrates rapid in 
vitro bactericidal activity in time kill studies in human plasma (Laue et al., 2009). Because of 
these findings, iclaprim is potentially well suited for treating patients with nosocomial 
pneumonia caused by susceptible and multidrug resistant pathogens.  In the present study, we 
investigated the effect of bovine pulmonary surfactant (BPS), a major component of epithelial 
lining fluid, on the antibacterial activity of iclaprim against common Gram-positive and Gram-
negative respiratory bacteria in vitro.   
 
2. Methods 
2.1 Collection of bacterial isolates 
  Clinical isolates were identified by the submitting laboratories and confirmed by JMI 
Laboratories using standard bacteriologic algorithms and methodologies, including Matrix-
Assisted Laser Desorption Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS).  
When necessary, MALDI-TOF MS was performed using the Bruker Daltonics MALDI Biotyper 
(Billerica, Massachusetts, USA), following manufacturer¶V instructions.  Isolates selected were 
from bacterial species commonly associated with pneumonia.  The clinical isolates were S. 
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pneumoniae (n=2), H. influenzae (n=1), M. catarrhalis (n=2),  S. aureus (n=1), and Klebsiella 
pneumoniae (n=1).  Table 2 shows the seven American Type Culture Collection (ATCC) 
reference strains that were tested.  The 14 isolates and strains in this study were similar to the 
numbers examined in prior studies of the effect of surfactant on in vitro activity of antimicrobials 
(Dallow et al, 2014 (n=18); Glacobbe et al 2017 (n=7); Gotfried et al, 2008 (n=2)).  The specific 
isolates were chosen because they were recent clinical isolates from species associated with 
pulmonary infections; the reference strains are frequently used ATCC QC reference strains.  
 
2.2 Susceptibility testing 
  Antibacterial susceptibility testing was measured by JMI Laboratories (North Liberty, 
Iowa, USA).  The seven nonduplicative, nonconsecutive clinical isolates were collected from US 
(n=4), Mexico (n=1), and Italy (n=2).  Susceptibility testing was performed by broth 
microdilution in accordance with the Clinical and Laboratory Standards Institute (CLSI) 
guidelines M07-A10 (2015) and the standard operating procedures at JMI Laboratories.  
Minimum inhibitory concentrations (MICs) were based on CLSI criteria (2015).  There are no 
published breakpoints for iclaprim, which is typical for drugs in development.  E. coli, K. 
pneumoniae, M. catarrhalis, E. faecalis, and S. aureus were tested in cation-adjusted Mueller-
Hinton broth (CA-MHB).  S. pneumoniae was tested in CA-MHB supplemented with 2.5-5% 
lysed horse blood, and H. influenzae was tested in Haemophilus Test Medium.  Quality control 
ranges and interpretation of results were performed in accordance with CLSI M100-S26 (2016) 
methods.  QC ranges for iclaprim were those approved by CLSI and published in M100-S26 
(2016). 
  Because bovine pulmonary surfactant can introduce cloudiness to the MIC testing media, 
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antimicrobial growth inhibition was also evaluated using the colorimetric metabolic indicator 
resazurin (Camlab Ltd., Cambridge, UK).  Following visual MIC value determinations, 10 µL of 
a resazurin solution (6.75 ± 7.0 mg/mL in H2O) was added to the test wells in each panel, and the 
panels were incubated for an additional 1-3 hours at 35ÛC in ambient atmosphere (Elshikh et al., 
2016; Sarker et al., 2007).  S. pneumoniae panels were omitted from resazurin analysis because 
the color change was obscured by the lysed horse blood present in the test medium.  Growth 
inhibition was then evaluated as a visible color change from blue (no growth) to pink (robust 
growth) and recorded as a MICRZ value.   
 
2.3 Pulmonary surfactant interaction 
  The MICs of iclaprim, levofloxacin, and daptomycin were measured against Gram-
positive and Gram-negative isolates.  Daptomycin was included as a positive control and 
levofloxacin was included as a negative control because published data showed an increase in 
daptomycin MICs but no increase in levofloxacin MICs in the presence of pulmonary surfactant 
(Silverman et al, 2005; Giacobbe et al, 2017). 
  A new vial of bovine pulmonary surfactant (BPS; Survanta®; Abbott Laboratories, 
Columbus, OH) was utilized for each independent experiment.  Each vial was mixed thoroughly 
and a 100 µL aliquot was spread on an agar growth plate, which was incubated overnight to 
confirm sterility.  BPS was added to the MIC test medium to a final concentration of 2.5% (v/v).  
The concentration of surfactant was expressed in terms of percent volume of Survanta® 
suspension, which consisted of phospholipid (25 mg/mL) and surfactant proteins (<1 mg/mL) in 
0.9% sodium chloride solution (Goerke, 1998).  The concentration of 2.5% was chosen because 
the effect of BPS on S. aureus daptomycin MIC values plateaus above approximately 1% 
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(Silverman et al, 2005; Dallow et al, 2014; Gotfriend et al, 2008) and because MIC values 
become difficult to read using CLSI methodology above 2.5%.  MICs of daptomycin were 
determined in CAMHB with the Ca2+ content adjusted to 50 mg/L. 
 
 
3. Results 
3.1 Pulmonary surfactant interaction  
Table 1 shows the MIC values of iclaprim, daptomycin, and levofloxacin with or without 
resazurin in the presence and absence of BPS.  Where applicable, all MICs for ATCC reference 
strains were within the ranges published by CLSI (CLSI, 2016) with the exception of iclaprim 
against E. coli ATCC 25922, where the MICs values were one two-fold dilution below the 
published QC range (Table 1).  The MIC and MICRZ values for all drug/isolate combinations 
agreed well in both the absence and presence of 2.5% (v/v) BPS.  The presence of BPS had 
minimal or no effect on the MIC and MICRZ values of iclaprim for any of the tested strains or 
isolates.  Most MICs and MICRZ values were unchanged, and where shifts were observed, these 
were only one drug dilution. In contrast, the MIC and MICRZ values of daptomycin against the 
respiratory Gram-positive reference strains and clinical isolates increased 16 to 128-fold to 16 
µg/mL in the presence of 2.5% BPS, consistent with published data (Dallow et al., 2014; 
Silverman et al. 2005).  As expected, the presence of BPS had little or no effect on the MIC and 
MICRZ values of levofloxacin (see Table 1). 
 
 
4. Discussion  
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In summary, this report demonstrates that iclaprim is active in vitro against common 
respiratory bacterial pathogens (S. pneumoniae, H. influenzae, S. aureus, K. pneumoniae and M. 
catarrhalis) even in the presence of pulmonary surfactant.  In contrast, the inhibitory effect of 
surfactant on antibacterial activity was observed with daptomycin.  This inhibitory MIC effect of 
surfactant on daptomycin activity has been reported to be mediated by binding of surfactant 
components to specific structures present on antibiotics, such as the the lipophilic side-chain of 
daptomycin (Silverman et al., 2005).   Thus, unlike daptomycin, the potency of iclaprim against 
common respiratory bacterial pathogens and the absence of antagonism by pulmonary surfactant 
against iclaprim shown in this in vitro study suggests that iclaprim should be active against 
pulmonary pathogens in pneumonia in vivo.   
A Phase 1 study investigated the tissue distribution of a single IV dose of iclaprim in 
relevant lung compartments (Andrews et al, 2007).  Iclaprim concentrations were found in 
epithelial ling fluid (ELF) and alveolar macrophages (AM), up to 20- and 40-fold higher, 
respectively, than in plasma.  In addition, iclaprim concentrations in plasma, ELF and AM after a 
single IV dose of 1.6 mg/kg exceeded iclaprim MICs for penicillin- susceptible S. pneumoniae 
(MIC90 0.06 mg/L) and methicillin-resistant S. aureus (MIC90 0.12 mg/L) for up to 7 hours; mean 
iclaprim concentrations in ELF exceeded the iclaprim MICs observed for S. pneumoniae with 
intermediate penicillin resistance (MIC90
 
2 mg/L) and full resistance (MIC90
 
4 mg/L) for up to 7 
and 4 hours, respectively.  
A Phase 2 study comparing the clinical cure rates of two iclaprim dosages with 
vancomycin in the treatment of patients with nosocomial pneumonia suspected or confirmed to 
be caused by Gram-positive pathogens showed iclaprim and vancomycin to have comparable 
clinical cure rates and safety profiles (Huang et al., submitted).  The cure rates in the intent-to-
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treat population were 73.9% (17 of 23), 62.5% (15 of 24), and 52.2% (12 of 23) at the post-
treatment test of cure visit in the iclaprim 0.8 mg/kg intravenous (IV) q12h, iclaprim 1.2 mg/kg 
IV q8h, and vancomycin 1 g IV q12h groups, respectively (iclaprim q12h versus vancomycin p = 
0.13; and iclaprim q8h versus vancomycin p = 0.47). The death rates within 28 days of the start 
of treatment were 8.7% (2 of 23), 12.5% (3 of 24), and 21.7% (5 of 23) for the iclaprim q12h, 
iclaprim q8h, and vancomycin groups, respectively (no statistically significant differences).  
Collectively, the current in vitro study, and previous Phase 1 and 2 studies support that iclaprim 
could be a potential treatment for pneumonia, including nosocomial pneumonia caused by 
susceptible and multidrug resistant Gram-positive bacteria. 
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Table 1  In vitro activity of iclaprim, daptomycin and levofloxacin in the presence and absence of 2.5% bovine pulmonary 
surfactant 
 
  
Iclaprim MIC (µg/mL) 
(80% read) 
 
Daptomycin MIC (µg/mL) 
 
Levofloxacin MIC (µg/mL) 
Species Source Strain CLSI 
CLSI 
BPS Resazurin 
Resazurin 
BPS   CLSI 
CLSI 
BPS Resazurin 
Resazurin 
BPS   CLSI 
CLSI 
BPS Resazurin 
Resazurin 
BPS 
E. coli ATCC 25922 0.5 0.5 1 1 
 
NDa ND ND ND 
 
0.015 0.03 0.015 0.03 
E. faecalis ATCC 29212     
 
2 >16 2 >16 
 
1 1 1 1 
E. faecalis ATCC 33186   0.03  
 
1 >16 1 >16 
 
4 1 4 2 
H. influenzae ATCC 49247 0.12 0.12 0.25 0.25 
 
ND ND ND ND 
 
0.03 0.03 0.03 0.03 
H. influenzae 
Clinical 
isolate 824704 0.06 0.06 0.06 0.06 
 
ND ND ND ND 
 
0.015 0.015 0.015 0.015 
K. pneumoniae ATCC 700603 4 4 4 4 
 
ND ND ND ND 
 
1 1 1 1 
K. pneumoniae 
Clinical 
isolate 858055 2 2 2 2 
 
ND ND ND ND 
 
0.06 0.12 0.06 0.06 
M. catarrhalis 
Clinical 
isolate 893806 4 ND 4 8 
 
8 ND 8 >16 
 
0.06 ND 0.06 0.06 
M. catarrhalis 
Clinical 
isolate 893807 4 ND 4 4 
 
8 ND 8 >16 
 
0.06 ND 0.06 0.06 
S. aureus ATCC 29213 0.06 0.06 0.06 0.06 
 
0.5 >16 0.5 >16 
 
0.25 0.12 0.25 0.12 
S. aureus 
Clinical 
isolate 825189 0.06 0.12 0.06 0.12 
 
0.25 >16 0.25 >16 
 
0.25 0.25 0.25 0.25 
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S. pneumoniae ATCC 49619 0.06 0.06 ND ND 
 
0.25 16 ND ND 
 
1 1 ND ND 
S. pneumoniae 
Clinical 
isolate 818757 0.06 0.06 ND ND 
 
0.25 16 ND ND 
 
1 1 ND ND 
S. pneumoniae 
Clinical 
isolate 825175 0.12 0.12 ND ND   0.25 16 ND ND   1 1 ND ND 
 
aND, not done (resazurin color change was difficult to interpret in the presence of blood or daptomycin was inactive 
against Gram-negative bacteria, or M. catarrhalis growth was difficult to interpret in the presence of BPS) 
 
Abbreviations: MIC, minimal inhibitory concentration; CLSI, Clinical and Laboratory Standards Institute; BPS, bovine pulmonary 
surfactant (Survanta®, tested at 2.5% v/v); ATCC, American Type Culture Collection
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Highlights 
x Iclaprim is active in vitro against common respiratory pathogens. 
x The in vitro activity of iclaprim is unchanged in pulmonary surfactant. 
x Iclaprim may be a treatment for pneumonia, including nosocomial pneumonia.  
